Supplemental Material from A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors

Authors:
  • ADAfshin Dowlati
    Afshin Dowlati
  • GVGordana Vlahovic
    Gordana Vlahovic
  • RNRonald B. Natale
    Ronald B. Natale
  • ERErik Rasmussen
    Erik Rasmussen
  • ISIndrajeet Singh
    Indrajeet Singh
  • YHYuying C. Hwang
    Yuying C. Hwang
  • JRJohn Rossi
    John Rossi
  • MBMichael B. Bass
    Michael B. Bass
  • GFGregory Friberg
    Gregory Friberg
  • CPCheryl A. Pickett
    Cheryl A. Pickett

Abstract
Supplemental Table 1 (Patient Incidence of Treatment-Related Adverse Events) and Supplemental Figure 1 (AMG 780 dose cohorts and patient enrollment)